VIROPHARMA INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY12 | FY11 | FY10 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | $33.3M | $222.1M | $211.7M |
| Net income | — | $36.4M | $21.3M |
| Total assets | $1.22B | $1.34B | $1.29B |
| Total liabilities | $462.9M | $445.7M | $396.4M |
| Equity | $757.0M | $891.1M | $891.1M |
| EPS (diluted) | $0.26 | $0.40 | $0.26 |
| Shares out. | 70.7M | 70.6M | 78.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2012- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- —
- Return on capital (ROCE)
- 3.0%
- Liabilities / assets
- 37.9%
- Debt / equity
- 0.61×
- Book value / share
- $10.70
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2012- Altman Z″ (distress)
- 4.58safe
- Piotroski F-Score
- 1/4weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 good- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Debt acceleration / triggering event · Delisting / listing-standard notice · Change in control · Director / officer change · Amended charter or bylawsJan 24, 2014
- Other material eventNov 14, 2013
- Entered a material agreement · Other material eventNov 12, 2013
- Results of operationsOct 31, 2013
- Other material eventSep 3, 2013
- Results of operations · Other material eventAug 1, 2013
- Other material eventJun 27, 2013
- Director / officer change · Shareholder voteMay 24, 2013
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC TO-I/AFORM SC TO-I/AFeb 25, 2014
- SC 13G/AFeb 14, 2014
- SC 13G/AFeb 14, 2014
- SC 13G/AFeb 14, 2014
- SC 13G/AFeb 12, 2014
- SC 13G/AFeb 10, 2014
- SC 13G/ASCHEDULE 13G/AFeb 10, 2014
- 15-12GFORM 15-12GFeb 4, 2014
- 4PRIMARY DOCUMENTJan 28, 2014
- 4PRIMARY DOCUMENTJan 28, 2014
- 4PRIMARY DOCUMENTJan 28, 2014
- 4PRIMARY DOCUMENTJan 28, 2014
- 4PRIMARY DOCUMENTJan 28, 2014
- 4PRIMARY DOCUMENTJan 28, 2014
- 4PRIMARY DOCUMENTJan 28, 2014